International Journal of Antimicrobial Agents

Papers
(The TQCC of International Journal of Antimicrobial Agents is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges3597
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial3233
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality1247
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?713
Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence696
Coronavirus disease 2019 (COVID-19): current status and future perspectives677
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19616
The epidemiology, diagnosis and treatment of COVID-19593
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection413
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies373
Chloroquine for the 2019 novel coronavirus SARS-CoV-2302
Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status253
Arguments in favour of remdesivir for treating SARS-CoV-2 infections238
Increased antimicrobial resistance during the COVID-19 pandemic232
Extra-respiratory manifestations of COVID-19218
Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking193
Teicoplanin: an alternative drug for the treatment of COVID-19?182
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies182
SARS-CoV-2 was already spreading in France in late December 2019181
Procalcitonin levels in COVID-19 patients177
Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein174
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine158
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update140
Tocilizumab for severe COVID-19: a systematic review and meta-analysis129
Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment114
Different mutations in SARS-CoV-2 associate with severe and mild outcome113
Ribavirin therapy for severe COVID-19: a retrospective cohort study111
Lactoferrin as potential preventative and adjunct treatment for COVID-19108
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants96
Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-1994
Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients85
Drug repositioning is an alternative for the treatment of coronavirus COVID-1985
Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-1982
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line81
COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies79
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic79
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study79
Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections79
Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment79
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal77
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-1976
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal75
Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.10594972
Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial66
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors65
Long-acting drugs and formulations for the treatment and prevention of HIV infection62
Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review60
Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients58
SARS-CoV-2: fear versus data56
Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial56
Combating devastating COVID-19 by drug repurposing56
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli51
Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?51
Erratum to ``A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence'' [International Journal of Antimicrobial Agents 55/6 (2020) 105948]50
Methylene blue inhibits replication of SARS-CoV-2 in vitro50
Addressing the challenges in antisepsis: focus on povidone iodine47
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine47
Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections45
HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance45
Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial44
Targeting antimicrobial drug resistance with marine natural products43
Occurrence of CTX-M-15- and MCR-1-producing Enterobacterales in pigs in Portugal: Evidence of direct links with antibiotic selective pressure43
Contributions of insertion sequences conferring colistin resistance in Klebsiella pneumoniae42
Cardiac effects and toxicity of chloroquine: a short update41
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin40
Colistin heteroresistance in Acinetobacter spp.: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications40
Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports39
Is teicoplanin a complementary treatment option for COVID-19? The question remains38
Colistin interacts synergistically with echinocandins against Candida auris36
Klebsiella pneumoniae infections in COVID-19 patients: a 2-month retrospective analysis in an Italian hospital36
In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection35
Octenidine: Novel insights into the detailed killing mechanism of Gram-negative bacteria at a cellular and molecular level35
In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumi35
A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?35
KPC-2-producing Klebsiella pneumoniae ST147 in a neonatal unit: Clonal isolates with differences in colistin susceptibility attributed to AcrAB-TolC pump34
Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin34
Emergence of a novel conjugative hybrid virulence multidrug-resistant plasmid in extensively drug-resistant Klebsiella pneumoniae ST1533
Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration–time curve against a trough 15–20 μg/mL concentration33
Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications33
Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection32
Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France32
Infections caused by naturally AmpC-producing Enterobacteriaceae: Can we use third-generation cephalosporins? A narrative review32
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals32
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial32
High prevalence of colistin resistance and mcr-9/10 genes in Enterobacter spp. in a tertiary hospital over a decade31
Interregional spread in Spain of linezolid-resistant Enterococcus spp. isolates carrying the optrA and poxtA genes30
Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infecti30
Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study29
A pharmacist-led prospective antibiotic stewardship intervention improves compliance to community-acquired pneumonia guidelines in 39 public and private hospitals across South Africa29
Oxygenated elansolid-type of polyketide spanned macrolides from a marine heterotrophic Bacillus as prospective antimicrobial agents against multidrug-resistant pathogens29
In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae28
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients28
Identification of mobile colistin resistance genes (mcr-1.1, mcr-5 and mcr-8.1) in Enterobacteriaceae and Alcaligenes faecalis of human and animal origin, Nigeria28
Epidemiology and prevalence of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae in humans, animals and the environment in West and Central Africa28
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited28
Bacteriophage–antibiotic combinations against ciprofloxacin/ceftriaxone-resistant Escherichia coli in vitro and in an experimental Galleria mellonella model27
An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis27
Chloroquine as a prophylactic agent against COVID-19?26
Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections26
Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?26
Artemisinin elevates ergosterol levels of Candida albicans to synergise with amphotericin B against oral candidiasis26
Inactivation of mgrB gene regulator and resistance to colistin is becoming endemic in carbapenem-resistant Klebsiella pneumoniae in Greece: A nationwide study from 2014 to 201726
Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris26
Antimicrobial stewardship programme: a vital resource for hospitals during the global outbreak of coronavirus disease 2019 (COVID-19)25
Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review25
Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia25
Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis24
Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort24
COVID-19 in hospitalised patients in Spain: a cohort study in Madrid24
Tocilizumab in COVID-19: Beware the risk of intestinal perforation24
Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections24
Diversity of amino acid substitutions in PmrCAB associated with colistin resistance in clinical isolates of Acinetobacter baumannii24
Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns23
Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies23
Extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in humans and from food-producing animals in Italy: a ‘One Health’ study23
Corticosteroid therapy for patients with COVID-19 pneumonia: a before–after study23
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany23
Meropenem–nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model23
Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination23
Effect of antibiotics on the human microbiome: a systematic review23
An insight into the implementation of the global action plan on antimicrobial resistance in the WHO African region: A roadmap for action22
Co-occurrence of aminoglycoside and β-lactam resistance mechanisms in aminoglycoside- non-susceptible Escherichia coli isolated in the Zurich area, Switzerland22
Evaluation of peptoid mimics of short, lipophilic peptide antimicrobials22
Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-201622
Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-222
Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy22
Repositioning of non-antibiotic drugs as an alternative to microbial resistance: a systematic review22
Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature22
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance21
Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March–June 202021
Genomic analysis of a pan-resistant Klebsiella pneumoniae sequence type 11 identified in Japan in 201621
Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections21
Synergism of sophoraflavanone G with norfloxacin against effluxing antibiotic-resistant Staphylococcus aureus20
Distribution of mcr genes among carbapenem-resistant Enterobacterales clinical isolates: high prevalence of mcr-positive Enterobacter cloacae complex in Seoul, Republic of Korea20
Molecular basis of antimicrobial resistance in Mycoplasma genitalium20
Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values20
A four-probiotic preparation for ventilator-associated pneumonia in multi-trauma patients: results of a randomized clinical trial20
Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 201920
Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care20
Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study20
Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model20
Co-existence of the oxazolidinone resistance genes cfr and optrA on two transferable multi-resistance plasmids in one Enterococcus faecalis isolate from swine20
Multidrug-resistant high-risk Enterococcus faecium clones: can we really define them?20
Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics20
β-lactam antibiotic versus combined β-lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis20
Biofilm-active antibiotic treatment improves the outcome of knee periprosthetic joint infection: Results from a 6-year prospective cohort study19
Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial19
Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems19
COVID-19 Therapeutic and Prevention19
Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies—need for data validation of the completed trials and to improve ongoing and future randomised trial designs19
Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa19
Antimicrobial dosing in critical care: A pragmatic adult dosing nomogram19
RamA upregulates multidrug resistance efflux pumps AcrAB and OqxAB in Klebsiella pneumoniae18
Therapeutic modalities and novel approaches in regenerative medicine for COVID-1918
Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients18
Antibacterial activity of griseofulvin analogues as an example of drug repurposing18
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept18
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes18
Polymyxin resistance in Enterobacterales: overview and epidemiology in the Americas18
Carbapenemase-producing Enterobacterales infections: recent advances in diagnosis and treatment18
Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-218
Circulation of multi-drug-resistant Shigella sonnei and Shigella flexneri among men who have sex with men in Barcelona, Spain, 2015–201918
Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices17
Evaluation of area under the concentration–time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury17
Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: A systematic review and17
In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portu17
The current state of laboratory mycology in Asia/Pacific: A survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM)17
Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper17
Emergence of a ST307 clone carrying a novel insertion element MITEKpn1 in the mgrB gene among carbapenem-resistant Klebsiella pneumoniae from Moscow, Russia17
In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015–201717
Cross-border emergence of clonal lineages of ST38 Escherichia coli producing the OXA-48-like carbapenemase OXA-244 in Germany and Switzerland17
Candida albicans biofilms: antifungal resistance, immune evasion, and emerging therapeutic strategies17
Colistin resistance genes mcr-1 to mcr-5, including a case of triple occurrence (mcr-1, -3 and -5), in Escherichia coli isolates from faeces of healthy pigs, cattle and poultry in Belgium, 2012–201616
Plasma exchange in the treatment of complex COVID-19-related critical illness: controversies and perspectives16
SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study16
Klebsiella pneumoniae Harboring Carbapenemase Genes in Taiwan: Its Evolution over 20 Years, 1998–201916
Hot topics in diabetic foot infection16
What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling16
Office-based approach to urinary tract infections in 50 000 patients: results from the REWIND study16
Fosfomycin for bacterial prostatitis: a review16
The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate β-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids16
Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance16
Heteroresistance to cefepime in Pseudomonas aeruginosa bacteraemia16
Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond16
Genomic and phenotypic characterisation of antimicrobial resistance in carbapenem-resistant Acinetobacter baumannii hyperendemic clones CC1, CC15, CC79 and CC2515
Colistin: from the shadows to a One Health approach for addressing antimicrobial resistance15
In vitro synergistic activity of NCL195 in combination with colistin against Gram-negative bacterial pathogens15
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-n15
Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations15
Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015–2017)15
Spinal implant-associated infections: a prospective multicentre cohort study15
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results15
Evolutionary landscapes of Pseudomonas aeruginosa towards ribosome-targeting antibiotic resistance depend on selection strength15
Evaluation of alternative antibiotics for susceptibility of gonococcal isolates from China15
Complex emergencies of COVID-19: management and experience in Zhuhai, China15
Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections15
Plasma medicine and wound management: Evaluation of the antibacterial efficacy of a medically certified cold atmospheric argon plasma jet15
Publishing in face of the COVID-19 pandemic15
Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by th15
Adaptation of a Russian population to SARS-CoV-2: Asymptomatic course, comorbidities, mortality, and other respiratory viruses – A reply to Fear versus Data15
Current trends in the real-life use of dalbavancin: report of a study panel15
Antimicrobial production by strictly anaerobic Clostridium spp.15
Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection15
Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study14
Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review14
Change in Antimicrobial Use During COVID-19 Pandemic in South Carolina Hospitals: A Multicenter Observational Cohort Study14
How preclinical infection models help define antibiotic doses in the clinic14
Phenotypic and WGS-derived antimicrobial resistance profiles of clinical and non-clinical Acinetobacter baumannii isolates from Germany and Vietnam14
LMB-1 producing Citrobacter freundii from Argentina, a novel player in the field of MBLs14
Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review14
Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data13
Widespread high-risk clones of multidrug-resistant extended-spectrum β-lactamase-producing Escherichia coli B2-ST131 and F-ST648 in public aquatic environments13
LPD-12: a promising lipopeptide to control COVID-1913
Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1Q119X mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales13
Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance13
Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study13
4-Ethoxybenzoic acid inhibits Staphylococcus aureus biofilm formation and potentiates biofilm sensitivity to vancomycin13
Efficacy of newly generated short antimicrobial cationic lipopeptides against methicillin-resistant Staphylococcus aureus (MRSA)13
Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice13
In vitro characterization, ADME analysis, and histological and toxicological evaluation of BM1, a macrocyclic amidinourea active against azole-resistant Candida strains13
Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli13
Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study13
Permeability enhancers sensitize β-lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to β-lactamase inhibitors, thereby restoring their β-lactam susceptibility13
Discovery of macrozones, new antimicrobial thiosemicarbazone-based azithromycin conjugates: design, synthesis and in vitro biological evaluation13
Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis13
Genotypes, carbapenemase carriage, integron diversity and oprD alterations among carbapenem-resistant Pseudomonas aeruginosa from Russia13
Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the13
Antibody-based strategies in HIV therapy13
Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines13
Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales13
Synergistic phage–surfactant combination clears IgE-promoted Staphylococcus aureus aggregation in vitro and enhances the effect in vivo13
Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing12
Recommended Antibiotic Dosage Regimens in Critically Ill Patients with Augmented Renal Clearance: A Systematic Review12
In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactam12
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)12
Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome rank12
Preferences regarding antibiotic treatment and the role of antibiotic resistance: A discrete choice experiment12
Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study12
The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections—A meta-analysis of randomized controlled trials12
Evaluation of early antibiotic use in patients with non‐severe COVID‐19 without bacterial infection12
Outpatient antibiotic use associated with acute upper respiratory infections in China: a nationwide cross-sectional study12
Vertical transmission and kidney damage in newborns whose mothers had coronavirus disease 2019 during pregnancy12
Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation12
Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy12
Impact of a non-compulsory antifungal stewardship program on overuse and misuse of antifungal agents in a tertiary care hospital11
Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-1911
Molecular genetic characteristics of mcr-9-harbouring Salmonella enterica serotype Typhimurium isolated from raw milk11
Effects of different resistance mechanisms on antimicrobial resistance in Acinetobacter baumannii: a strategic system for screening and activity testing of new antibiotics11
Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii11
Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics11
0.082567930221558